Breaking News, Collaborations & Alliances

Innovent Biologics, SanegeneBio Partner on siRNA Hypertension Drug

Innovent obtains exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Innovent Biologics, a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major diseases, and SanegeneBio have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters